Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally with the Everads Injector in AdultS with GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

Next Previous
X
Search
Trial Profile

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally with the Everads Injector in AdultS with GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KRIYA 825 (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms the VISION Study; VISION
  • Sponsors Kriya Therapeutics

    • Most Recent Events

    • 27 Feb 2025 Planned initiation date changed from 9 Jan 2025 to 1 Mar 2025.
    • 27 Feb 2025 Status changed from not yet recruiting to recruiting.
    • 15 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top